CLINICAL CHEMISTRY HARR
問題一覧
1
D. Reject the sample because the citrate will interfere
2
C. Highest levels are seen in Duchenne’s muscular dystrophy
3
C. CK-MB is more specific than myoglobin
4
B. 3.2%
5
A. An increase in CK-MB that is persistent
6
B. Levels below 100 μg/L on admission and 2–4 hours postadmission help to exclude a diagnosis of AMI
7
C. Abnormal within 2 hours; peaks within 12 hours; returns to normal in 36 hours
8
C. Abnormal within 4 hours; peaks within 24 hours; returns to normal in 1 week
9
C. Admission, 3 hours, 6 hours, and a final sample within 12 hours
10
B. The upper 99th percentile or lowest level that can be measured with 10% CV
11
B. Troponin T
12
D. No evidence of myocardial or skeletal muscle injury
13
A. This patient has had an AMI and further testing is unnecessary
14
C. The patient has suffered cardiac injury
15
C. Albumin cobalt binding
16
D. High-sensitivity C-reactive protein
17
C. A normal test result (<100 pg/mL) helps rule out congestive heart failure in persons with symptoms associated with coronary insufficiency
18
B. High plasma levels are associated with atherosclerosis and increased risk of thrombosis
19
D. Myeloperoxidase (MPO)
20
B. Both transfer an amino group to α–ketoglutarate
21
B. Oxaloacetate and glutamate
22
C. Pyruvate and glutamate
23
A. Hemolysis will cause positive interference in both AST and ALT assays
24
B. Malate dehydrogenase
25
B. Rapidly exhausts endogenous pyruvate in the lag phase
26
C. SGPT is the older abbreviation for ALT
27
B. AST peaks 24–48 hours after an AMI and returns to normal within 4–6 days
28
A. Acute hepatitis
29
A. Acute hepatitis
30
C. Hepatic cancer
31
C. ALT is far more specific for liver diseases than is AST
32
D. γ-Glutamyltransferase (GGT)
33
D. LD
34
B. They are divided into two classes based upon pH needed for activity
35
D. Pregnant women have a higher level of serum ALP than other adults
36
D. Placental
37
C. Liver
38
A. The bone isoenzyme can be measured immunochemically
39
C. Elevated serum ALP seen with elevated GGT suggests a hepatic source
40
A. Small cell lung carcinoma
41
D. Osteoporosis
42
A. p-Nitrophenyl phosphate
43
C. 2-Amino-2-methyl-1-propanol
44
D. Bone disease or malignancy
45
B. Measuring the enzyme in a vaginal swab extract
46
A. Hydrolyzes second α 1–4 glycosidic linkages of starch, glycogen, and other polyglucans
47
D. Blocked maltohepatoside
48
B. 2–12 hours
49
B. Diagnostic sensitivity is increased by assaying both amylase and lipase
50
A. Mumps
51
B. Activity will vary depending on the method used
52
C. Synthetic substrates can be conjugated to p-nitrophenol (PNP) for a kinetic assay
53
A. Other esterases can hydrolyze triglyceride and synthetic diglycerides
54
A. Lipase is not increased in mumps, malignancy, or ectopic pregnancy
55
C. Titration of fatty acids with dilute NaOH following controlled incubation of serum with olive oil
56
D. Peroxidase coupling
57
C. Pseudocholinesterase
58
C. Aldolase
59
B. Glucose-6-phosphate dehydrogenase
60
A. Estriol (E3)
61
D. Low serum electrolytes
62
D. Prolactin
63
A. Gastrin
64
A. It is associated with hyperplasia or neoplasia of at least two endocrine organs
65
B. Estradiol (E2 )
66
C. Both hormones normally peak 1–2 days before ovulation
67
A. Prolactin
68
A. Increased LH, FSH, and decreased testosterone
69
C. At the midcycle just after LH peaks
70
D. Testosterone and dehydroepiandrosterone sulfate
71
B. Decreased LH, FSH, and estrogen
72
C. Decreased estrogen and progesterone, and increased LH and FSH
73
A. Pituitary failure may involve one, several, or all adenohypophyseal hormones; but GH deficiency is usually found
74
B. Some patients will require a glucose suppression test to establish a diagnosis
75
C. Hypophosphatemia
76
C. PTH levels differentiate primary and secondary causes of hypocalcemia
77
C. Both the amino-terminal fragment and intact PTH
78
C. Parathyroid hormone–related protein (PTHRP)
79
A. Cortisol
80
B. Cushing’s syndrome is associated with glucose intolerance
81
A. Twenty-four–hour urinary free cortisol is a more sensitive test than plasma total cortisol
82
C. Conn’s syndrome
83
C. Overuse of corticosteroids
84
A. Excess secretion of pituitary ACTH
85
C. In congenital adrenal hyperplasia
86
C. Serum ACTH
87
A. Overnight low-dose dexamethasone suppression test
88
D. Petrosal sinus sampling following corticotropin-releasing hormone stimulation
89
B. Primary and secondary Addison’s disease can often be differentiated by plasma ACTH
90
C. Plasma levels show both diurnal and pulsed variation
91
D. Metanephrines
92
A. 5-Hydroxyindolacetic acid (5-HIAA
93
B. Twenty-four–hour urinary catecholamine assay avoids pulse variations associated with measurement of plasma catecholamines
94
B. Measurement by HPLC with electrochemical detection
95
C. Twenty-four–hour urine creatinine should be measured with vanillylmandelic acid, homovanillic acid, or metanephrines
96
D. Both can be measured by specific HPLC and MS assays
97
B. Neuroblastoma
98
C. Tyrosine
99
B. T3 is about 10-fold more active than T4
100
B. Total T3 and T4 are influenced by the level of thyroxine-binding globulin
other names parasitology
other names parasitology
Yves Laure Pimentel · 70問 · 2年前other names parasitology
other names parasitology
70問 • 2年前PARASITOLOGY
PARASITOLOGY
Yves Laure Pimentel · 111問 · 2年前PARASITOLOGY
PARASITOLOGY
111問 • 2年前HTMLBE
HTMLBE
Yves Laure Pimentel · 64問 · 2年前HTMLBE
HTMLBE
64問 • 2年前CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR
CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR
Yves Laure Pimentel · 61問 · 2年前CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR
CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR
61問 • 2年前HISTOPATHOLOGY
HISTOPATHOLOGY
Yves Laure Pimentel · 69問 · 2年前HISTOPATHOLOGY
HISTOPATHOLOGY
69問 • 2年前CC-2 SPECTROPHOTOMETRY
CC-2 SPECTROPHOTOMETRY
Yves Laure Pimentel · 100問 · 2年前CC-2 SPECTROPHOTOMETRY
CC-2 SPECTROPHOTOMETRY
100問 • 2年前CC-3 ELECTROPHORESIS
CC-3 ELECTROPHORESIS
Yves Laure Pimentel · 41問 · 2年前CC-3 ELECTROPHORESIS
CC-3 ELECTROPHORESIS
41問 • 2年前AUBF LAB SAFETY
AUBF LAB SAFETY
Yves Laure Pimentel · 87問 · 2年前AUBF LAB SAFETY
AUBF LAB SAFETY
87問 • 2年前CSF 1
CSF 1
Yves Laure Pimentel · 100問 · 2年前CSF 1
CSF 1
100問 • 2年前CSF 2
CSF 2
Yves Laure Pimentel · 82問 · 2年前CSF 2
CSF 2
82問 • 2年前SEMEN 1
SEMEN 1
Yves Laure Pimentel · 100問 · 2年前SEMEN 1
SEMEN 1
100問 • 2年前SEMEN 2
SEMEN 2
Yves Laure Pimentel · 7問 · 2年前SEMEN 2
SEMEN 2
7問 • 2年前SYNOVIAL FLUID 1
SYNOVIAL FLUID 1
Yves Laure Pimentel · 100問 · 2年前SYNOVIAL FLUID 1
SYNOVIAL FLUID 1
100問 • 2年前SYNOVIAL FLUID 2
SYNOVIAL FLUID 2
Yves Laure Pimentel · 6問 · 2年前SYNOVIAL FLUID 2
SYNOVIAL FLUID 2
6問 • 2年前SEROUS FLUID
SEROUS FLUID
Yves Laure Pimentel · 25問 · 2年前SEROUS FLUID
SEROUS FLUID
25問 • 2年前PLEURAL FLUID
PLEURAL FLUID
Yves Laure Pimentel · 44問 · 2年前PLEURAL FLUID
PLEURAL FLUID
44問 • 2年前PERICARDIAL FLUID
PERICARDIAL FLUID
Yves Laure Pimentel · 18問 · 2年前PERICARDIAL FLUID
PERICARDIAL FLUID
18問 • 2年前PERITONEAL FLUID/ ASCITIC FLUID
PERITONEAL FLUID/ ASCITIC FLUID
Yves Laure Pimentel · 30問 · 2年前PERITONEAL FLUID/ ASCITIC FLUID
PERITONEAL FLUID/ ASCITIC FLUID
30問 • 2年前AMNIOTIC FLUID
AMNIOTIC FLUID
Yves Laure Pimentel · 92問 · 2年前AMNIOTIC FLUID
AMNIOTIC FLUID
92問 • 2年前FECALYSIS
FECALYSIS
Yves Laure Pimentel · 80問 · 2年前FECALYSIS
FECALYSIS
80問 • 2年前OTHER BODY FLUIDS
OTHER BODY FLUIDS
Yves Laure Pimentel · 89問 · 2年前OTHER BODY FLUIDS
OTHER BODY FLUIDS
89問 • 2年前MTLBE- SUHO NOTES
MTLBE- SUHO NOTES
Yves Laure Pimentel · 86問 · 2年前MTLBE- SUHO NOTES
MTLBE- SUHO NOTES
86問 • 2年前MTLBE..
MTLBE..
Yves Laure Pimentel · 35問 · 2年前MTLBE..
MTLBE..
35問 • 2年前CC- CHROMATOGRAPHY
CC- CHROMATOGRAPHY
Yves Laure Pimentel · 19問 · 1年前CC- CHROMATOGRAPHY
CC- CHROMATOGRAPHY
19問 • 1年前CC-OSMOMETRY
CC-OSMOMETRY
Yves Laure Pimentel · 14問 · 1年前CC-OSMOMETRY
CC-OSMOMETRY
14問 • 1年前CC-ELECTROCHEMISTRY TECHNIQUES
CC-ELECTROCHEMISTRY TECHNIQUES
Yves Laure Pimentel · 43問 · 1年前CC-ELECTROCHEMISTRY TECHNIQUES
CC-ELECTROCHEMISTRY TECHNIQUES
43問 • 1年前CC- CARBOHYDRATES
CC- CARBOHYDRATES
Yves Laure Pimentel · 49問 · 2年前CC- CARBOHYDRATES
CC- CARBOHYDRATES
49問 • 2年前CC- DIABETES MELLITUS
CC- DIABETES MELLITUS
Yves Laure Pimentel · 97問 · 2年前CC- DIABETES MELLITUS
CC- DIABETES MELLITUS
97問 • 2年前MAJOR LIPOPROTEINS
MAJOR LIPOPROTEINS
Yves Laure Pimentel · 57問 · 2年前MAJOR LIPOPROTEINS
MAJOR LIPOPROTEINS
57問 • 2年前MINOR LIPOPROTEINS
MINOR LIPOPROTEINS
Yves Laure Pimentel · 63問 · 2年前MINOR LIPOPROTEINS
MINOR LIPOPROTEINS
63問 • 2年前PROTEINS
PROTEINS
Yves Laure Pimentel · 37問 · 2年前PROTEINS
PROTEINS
37問 • 2年前PLASMA PROTEINS 1
PLASMA PROTEINS 1
Yves Laure Pimentel · 91問 · 2年前PLASMA PROTEINS 1
PLASMA PROTEINS 1
91問 • 2年前PLASMA PROTEINS 2 (ALPHA 2 REGION)
PLASMA PROTEINS 2 (ALPHA 2 REGION)
Yves Laure Pimentel · 98問 · 2年前PLASMA PROTEINS 2 (ALPHA 2 REGION)
PLASMA PROTEINS 2 (ALPHA 2 REGION)
98問 • 2年前MISCELLANEOUS PROTEINS
MISCELLANEOUS PROTEINS
Yves Laure Pimentel · 61問 · 2年前MISCELLANEOUS PROTEINS
MISCELLANEOUS PROTEINS
61問 • 2年前Liver Function Test 1
Liver Function Test 1
Yves Laure Pimentel · 100問 · 2年前Liver Function Test 1
Liver Function Test 1
100問 • 2年前Liver Function Test 2
Liver Function Test 2
Yves Laure Pimentel · 96問 · 2年前Liver Function Test 2
Liver Function Test 2
96問 • 2年前TUMOR MARKERS
TUMOR MARKERS
Yves Laure Pimentel · 33問 · 2年前TUMOR MARKERS
TUMOR MARKERS
33問 • 2年前KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE
KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE
Yves Laure Pimentel · 41問 · 2年前KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE
KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE
41問 • 2年前GLYCOGEN STORAGE DISEASES
GLYCOGEN STORAGE DISEASES
Yves Laure Pimentel · 17問 · 2年前GLYCOGEN STORAGE DISEASES
GLYCOGEN STORAGE DISEASES
17問 • 2年前LIPID STORAGE DISEASES
LIPID STORAGE DISEASES
Yves Laure Pimentel · 14問 · 2年前LIPID STORAGE DISEASES
LIPID STORAGE DISEASES
14問 • 2年前PROTEINS
PROTEINS
Yves Laure Pimentel · 71問 · 2年前PROTEINS
PROTEINS
71問 • 2年前QUICK FIRE- ELECTRODES
QUICK FIRE- ELECTRODES
Yves Laure Pimentel · 7問 · 2年前QUICK FIRE- ELECTRODES
QUICK FIRE- ELECTRODES
7問 • 2年前ELECTROLYTES
ELECTROLYTES
Yves Laure Pimentel · 10問 · 2年前ELECTROLYTES
ELECTROLYTES
10問 • 2年前DRUGS
DRUGS
Yves Laure Pimentel · 27問 · 2年前DRUGS
DRUGS
27問 • 2年前TOXIC AGENTS:
TOXIC AGENTS:
Yves Laure Pimentel · 12問 · 2年前TOXIC AGENTS:
TOXIC AGENTS:
12問 • 2年前HEMATOLOGY 1 (HEMATOPOIESIS 1)
HEMATOLOGY 1 (HEMATOPOIESIS 1)
Yves Laure Pimentel · 100問 · 2年前HEMATOLOGY 1 (HEMATOPOIESIS 1)
HEMATOLOGY 1 (HEMATOPOIESIS 1)
100問 • 2年前HEMATOLOGY (HEMATOPOIESIS 2)
HEMATOLOGY (HEMATOPOIESIS 2)
Yves Laure Pimentel · 29問 · 2年前HEMATOLOGY (HEMATOPOIESIS 2)
HEMATOLOGY (HEMATOPOIESIS 2)
29問 • 2年前hema diseases
hema diseases
Yves Laure Pimentel · 25問 · 2年前hema diseases
hema diseases
25問 • 2年前AML
AML
Yves Laure Pimentel · 43問 · 2年前AML
AML
43問 • 2年前GLOBIN SYNTHESIS
GLOBIN SYNTHESIS
Yves Laure Pimentel · 71問 · 2年前GLOBIN SYNTHESIS
GLOBIN SYNTHESIS
71問 • 2年前HEMATOLOGY REFERENCE RANGES
HEMATOLOGY REFERENCE RANGES
Yves Laure Pimentel · 31問 · 2年前HEMATOLOGY REFERENCE RANGES
HEMATOLOGY REFERENCE RANGES
31問 • 2年前DISORDERS OF PRIMARY HEMOSTASIS
DISORDERS OF PRIMARY HEMOSTASIS
Yves Laure Pimentel · 34問 · 2年前DISORDERS OF PRIMARY HEMOSTASIS
DISORDERS OF PRIMARY HEMOSTASIS
34問 • 2年前PLATELET DISORDERS
PLATELET DISORDERS
Yves Laure Pimentel · 37問 · 2年前PLATELET DISORDERS
PLATELET DISORDERS
37問 • 2年前CHARACTERISTICS OF CLOTTING FACTORS
CHARACTERISTICS OF CLOTTING FACTORS
Yves Laure Pimentel · 100問 · 2年前CHARACTERISTICS OF CLOTTING FACTORS
CHARACTERISTICS OF CLOTTING FACTORS
100問 • 2年前4. CLASSIFICATION OF MACROPHAGE
4. CLASSIFICATION OF MACROPHAGE
Yves Laure Pimentel · 12問 · 2年前4. CLASSIFICATION OF MACROPHAGE
4. CLASSIFICATION OF MACROPHAGE
12問 • 2年前3. NATURAL OR INNATE IMMUNITY
3. NATURAL OR INNATE IMMUNITY
Yves Laure Pimentel · 39問 · 2年前3. NATURAL OR INNATE IMMUNITY
3. NATURAL OR INNATE IMMUNITY
39問 • 2年前5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)
5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)
Yves Laure Pimentel · 55問 · 2年前5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)
5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)
55問 • 2年前6. PHAGOCYTOSIS Chemotaxis
6. PHAGOCYTOSIS Chemotaxis
Yves Laure Pimentel · 37問 · 2年前6. PHAGOCYTOSIS Chemotaxis
6. PHAGOCYTOSIS Chemotaxis
37問 • 2年前8. NATURE OF ANTIGEN
8. NATURE OF ANTIGEN
Yves Laure Pimentel · 44問 · 2年前8. NATURE OF ANTIGEN
8. NATURE OF ANTIGEN
44問 • 2年前9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN
9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN
Yves Laure Pimentel · 50問 · 2年前9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN
9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN
50問 • 2年前1. HISTORY
1. HISTORY
Yves Laure Pimentel · 69問 · 2年前1. HISTORY
1. HISTORY
69問 • 2年前2. TYPES OF IMMUNITY
2. TYPES OF IMMUNITY
Yves Laure Pimentel · 38問 · 2年前2. TYPES OF IMMUNITY
2. TYPES OF IMMUNITY
38問 • 2年前7. PHAGOCYTOSIS Engulfment and Digestion
7. PHAGOCYTOSIS Engulfment and Digestion
Yves Laure Pimentel · 21問 · 2年前7. PHAGOCYTOSIS Engulfment and Digestion
7. PHAGOCYTOSIS Engulfment and Digestion
21問 • 2年前8. PHAGOCYTOSIS EXOCYTOSIS
8. PHAGOCYTOSIS EXOCYTOSIS
Yves Laure Pimentel · 15問 · 2年前8. PHAGOCYTOSIS EXOCYTOSIS
8. PHAGOCYTOSIS EXOCYTOSIS
15問 • 2年前10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)
10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)
Yves Laure Pimentel · 32問 · 2年前10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)
10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)
32問 • 2年前11. TRANSPLANTATION IMMUNOLOGY
11. TRANSPLANTATION IMMUNOLOGY
Yves Laure Pimentel · 30問 · 2年前11. TRANSPLANTATION IMMUNOLOGY
11. TRANSPLANTATION IMMUNOLOGY
30問 • 2年前2. LYMPHOID ORGANS
2. LYMPHOID ORGANS
Yves Laure Pimentel · 38問 · 2年前2. LYMPHOID ORGANS
2. LYMPHOID ORGANS
38問 • 2年前3. CLUSTER OF DIFFERENTIATION
3. CLUSTER OF DIFFERENTIATION
Yves Laure Pimentel · 48問 · 2年前3. CLUSTER OF DIFFERENTIATION
3. CLUSTER OF DIFFERENTIATION
48問 • 2年前4. T-CELL DIFFERENTIATION
4. T-CELL DIFFERENTIATION
Yves Laure Pimentel · 35問 · 2年前4. T-CELL DIFFERENTIATION
4. T-CELL DIFFERENTIATION
35問 • 2年前5. T CELL IMMUNODEFICIENCIES
5. T CELL IMMUNODEFICIENCIES
Yves Laure Pimentel · 18問 · 2年前5. T CELL IMMUNODEFICIENCIES
5. T CELL IMMUNODEFICIENCIES
18問 • 2年前6. STAGES IN B-CELL DIFFERENTIATION PROPIMAP
6. STAGES IN B-CELL DIFFERENTIATION PROPIMAP
Yves Laure Pimentel · 44問 · 2年前6. STAGES IN B-CELL DIFFERENTIATION PROPIMAP
6. STAGES IN B-CELL DIFFERENTIATION PROPIMAP
44問 • 2年前7. B CELL IMMUNODEFICIENCIES
7. B CELL IMMUNODEFICIENCIES
Yves Laure Pimentel · 23問 · 2年前7. B CELL IMMUNODEFICIENCIES
7. B CELL IMMUNODEFICIENCIES
23問 • 2年前8. COMBINED T CELL AND B CELL DEFICIENCIES
8. COMBINED T CELL AND B CELL DEFICIENCIES
Yves Laure Pimentel · 34問 · 2年前8. COMBINED T CELL AND B CELL DEFICIENCIES
8. COMBINED T CELL AND B CELL DEFICIENCIES
34問 • 2年前9. COMPARISON OF T AND B CELLS
9. COMPARISON OF T AND B CELLS
Yves Laure Pimentel · 12問 · 2年前9. COMPARISON OF T AND B CELLS
9. COMPARISON OF T AND B CELLS
12問 • 2年前10. LABORATORY IDENTIFICATION OF LYMPHOCYTES
10. LABORATORY IDENTIFICATION OF LYMPHOCYTES
Yves Laure Pimentel · 16問 · 2年前10. LABORATORY IDENTIFICATION OF LYMPHOCYTES
10. LABORATORY IDENTIFICATION OF LYMPHOCYTES
16問 • 2年前11. NATURAL KILLER CELLS OR THIRD POPULATION CELL
11. NATURAL KILLER CELLS OR THIRD POPULATION CELL
Yves Laure Pimentel · 15問 · 2年前11. NATURAL KILLER CELLS OR THIRD POPULATION CELL
11. NATURAL KILLER CELLS OR THIRD POPULATION CELL
15問 • 2年前12. ANTIBODY
12. ANTIBODY
Yves Laure Pimentel · 79問 · 2年前12. ANTIBODY
12. ANTIBODY
79問 • 2年前13. TYPES OF ANTIBODIES
13. TYPES OF ANTIBODIES
Yves Laure Pimentel · 97問 · 2年前13. TYPES OF ANTIBODIES
13. TYPES OF ANTIBODIES
97問 • 2年前14. MONOCLONAL ANTIBODIES
14. MONOCLONAL ANTIBODIES
Yves Laure Pimentel · 11問 · 2年前14. MONOCLONAL ANTIBODIES
14. MONOCLONAL ANTIBODIES
11問 • 2年前1. INTERLEUKINS
1. INTERLEUKINS
Yves Laure Pimentel · 23問 · 2年前1. INTERLEUKINS
1. INTERLEUKINS
23問 • 2年前2. INTERFERONS
2. INTERFERONS
Yves Laure Pimentel · 28問 · 2年前2. INTERFERONS
2. INTERFERONS
28問 • 2年前3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY
3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY
Yves Laure Pimentel · 8問 · 2年前3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY
3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY
8問 • 2年前4. COMPLEMENT SYSTEM
4. COMPLEMENT SYSTEM
Yves Laure Pimentel · 19問 · 2年前4. COMPLEMENT SYSTEM
4. COMPLEMENT SYSTEM
19問 • 2年前15. COMPLEMENT SYSTEM
15. COMPLEMENT SYSTEM
Yves Laure Pimentel · 76問 · 2年前15. COMPLEMENT SYSTEM
15. COMPLEMENT SYSTEM
76問 • 2年前16. SYSTEM CONTROLS/COMPLEMENT REGULATION
16. SYSTEM CONTROLS/COMPLEMENT REGULATION
Yves Laure Pimentel · 21問 · 2年前16. SYSTEM CONTROLS/COMPLEMENT REGULATION
16. SYSTEM CONTROLS/COMPLEMENT REGULATION
21問 • 2年前17. COMPLEMENT AND DISEASE STATES
17. COMPLEMENT AND DISEASE STATES
Yves Laure Pimentel · 29問 · 2年前17. COMPLEMENT AND DISEASE STATES
17. COMPLEMENT AND DISEASE STATES
29問 • 2年前18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)
18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)
Yves Laure Pimentel · 19問 · 2年前18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)
18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)
19問 • 2年前19. CYTOKINES
19. CYTOKINES
Yves Laure Pimentel · 22問 · 2年前19. CYTOKINES
19. CYTOKINES
22問 • 2年前20. INTERLEUKINS
20. INTERLEUKINS
Yves Laure Pimentel · 24問 · 2年前20. INTERLEUKINS
20. INTERLEUKINS
24問 • 2年前21. INTERFERONS, TNF, TGF, CHEMOKINE
21. INTERFERONS, TNF, TGF, CHEMOKINE
Yves Laure Pimentel · 21問 · 2年前21. INTERFERONS, TNF, TGF, CHEMOKINE
21. INTERFERONS, TNF, TGF, CHEMOKINE
21問 • 2年前1. SERO
1. SERO
Yves Laure Pimentel · 54問 · 2年前1. SERO
1. SERO
54問 • 2年前2. PRECIPITATION
2. PRECIPITATION
Yves Laure Pimentel · 38問 · 2年前2. PRECIPITATION
2. PRECIPITATION
38問 • 2年前3. PASSIVE IMMUNODIFFUSION
3. PASSIVE IMMUNODIFFUSION
Yves Laure Pimentel · 17問 · 2年前3. PASSIVE IMMUNODIFFUSION
3. PASSIVE IMMUNODIFFUSION
17問 • 2年前4. OUCHTERLONY
4. OUCHTERLONY
Yves Laure Pimentel · 15問 · 2年前4. OUCHTERLONY
4. OUCHTERLONY
15問 • 2年前5. ELECTROPHORETIC TECHNIQUE
5. ELECTROPHORETIC TECHNIQUE
Yves Laure Pimentel · 9問 · 2年前5. ELECTROPHORETIC TECHNIQUE
5. ELECTROPHORETIC TECHNIQUE
9問 • 2年前6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)
6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)
Yves Laure Pimentel · 11問 · 2年前6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)
6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)
11問 • 2年前7. IMMUNOFIXATION ELECTROPHORESIS
7. IMMUNOFIXATION ELECTROPHORESIS
Yves Laure Pimentel · 29問 · 2年前7. IMMUNOFIXATION ELECTROPHORESIS
7. IMMUNOFIXATION ELECTROPHORESIS
29問 • 2年前問題一覧
1
D. Reject the sample because the citrate will interfere
2
C. Highest levels are seen in Duchenne’s muscular dystrophy
3
C. CK-MB is more specific than myoglobin
4
B. 3.2%
5
A. An increase in CK-MB that is persistent
6
B. Levels below 100 μg/L on admission and 2–4 hours postadmission help to exclude a diagnosis of AMI
7
C. Abnormal within 2 hours; peaks within 12 hours; returns to normal in 36 hours
8
C. Abnormal within 4 hours; peaks within 24 hours; returns to normal in 1 week
9
C. Admission, 3 hours, 6 hours, and a final sample within 12 hours
10
B. The upper 99th percentile or lowest level that can be measured with 10% CV
11
B. Troponin T
12
D. No evidence of myocardial or skeletal muscle injury
13
A. This patient has had an AMI and further testing is unnecessary
14
C. The patient has suffered cardiac injury
15
C. Albumin cobalt binding
16
D. High-sensitivity C-reactive protein
17
C. A normal test result (<100 pg/mL) helps rule out congestive heart failure in persons with symptoms associated with coronary insufficiency
18
B. High plasma levels are associated with atherosclerosis and increased risk of thrombosis
19
D. Myeloperoxidase (MPO)
20
B. Both transfer an amino group to α–ketoglutarate
21
B. Oxaloacetate and glutamate
22
C. Pyruvate and glutamate
23
A. Hemolysis will cause positive interference in both AST and ALT assays
24
B. Malate dehydrogenase
25
B. Rapidly exhausts endogenous pyruvate in the lag phase
26
C. SGPT is the older abbreviation for ALT
27
B. AST peaks 24–48 hours after an AMI and returns to normal within 4–6 days
28
A. Acute hepatitis
29
A. Acute hepatitis
30
C. Hepatic cancer
31
C. ALT is far more specific for liver diseases than is AST
32
D. γ-Glutamyltransferase (GGT)
33
D. LD
34
B. They are divided into two classes based upon pH needed for activity
35
D. Pregnant women have a higher level of serum ALP than other adults
36
D. Placental
37
C. Liver
38
A. The bone isoenzyme can be measured immunochemically
39
C. Elevated serum ALP seen with elevated GGT suggests a hepatic source
40
A. Small cell lung carcinoma
41
D. Osteoporosis
42
A. p-Nitrophenyl phosphate
43
C. 2-Amino-2-methyl-1-propanol
44
D. Bone disease or malignancy
45
B. Measuring the enzyme in a vaginal swab extract
46
A. Hydrolyzes second α 1–4 glycosidic linkages of starch, glycogen, and other polyglucans
47
D. Blocked maltohepatoside
48
B. 2–12 hours
49
B. Diagnostic sensitivity is increased by assaying both amylase and lipase
50
A. Mumps
51
B. Activity will vary depending on the method used
52
C. Synthetic substrates can be conjugated to p-nitrophenol (PNP) for a kinetic assay
53
A. Other esterases can hydrolyze triglyceride and synthetic diglycerides
54
A. Lipase is not increased in mumps, malignancy, or ectopic pregnancy
55
C. Titration of fatty acids with dilute NaOH following controlled incubation of serum with olive oil
56
D. Peroxidase coupling
57
C. Pseudocholinesterase
58
C. Aldolase
59
B. Glucose-6-phosphate dehydrogenase
60
A. Estriol (E3)
61
D. Low serum electrolytes
62
D. Prolactin
63
A. Gastrin
64
A. It is associated with hyperplasia or neoplasia of at least two endocrine organs
65
B. Estradiol (E2 )
66
C. Both hormones normally peak 1–2 days before ovulation
67
A. Prolactin
68
A. Increased LH, FSH, and decreased testosterone
69
C. At the midcycle just after LH peaks
70
D. Testosterone and dehydroepiandrosterone sulfate
71
B. Decreased LH, FSH, and estrogen
72
C. Decreased estrogen and progesterone, and increased LH and FSH
73
A. Pituitary failure may involve one, several, or all adenohypophyseal hormones; but GH deficiency is usually found
74
B. Some patients will require a glucose suppression test to establish a diagnosis
75
C. Hypophosphatemia
76
C. PTH levels differentiate primary and secondary causes of hypocalcemia
77
C. Both the amino-terminal fragment and intact PTH
78
C. Parathyroid hormone–related protein (PTHRP)
79
A. Cortisol
80
B. Cushing’s syndrome is associated with glucose intolerance
81
A. Twenty-four–hour urinary free cortisol is a more sensitive test than plasma total cortisol
82
C. Conn’s syndrome
83
C. Overuse of corticosteroids
84
A. Excess secretion of pituitary ACTH
85
C. In congenital adrenal hyperplasia
86
C. Serum ACTH
87
A. Overnight low-dose dexamethasone suppression test
88
D. Petrosal sinus sampling following corticotropin-releasing hormone stimulation
89
B. Primary and secondary Addison’s disease can often be differentiated by plasma ACTH
90
C. Plasma levels show both diurnal and pulsed variation
91
D. Metanephrines
92
A. 5-Hydroxyindolacetic acid (5-HIAA
93
B. Twenty-four–hour urinary catecholamine assay avoids pulse variations associated with measurement of plasma catecholamines
94
B. Measurement by HPLC with electrochemical detection
95
C. Twenty-four–hour urine creatinine should be measured with vanillylmandelic acid, homovanillic acid, or metanephrines
96
D. Both can be measured by specific HPLC and MS assays
97
B. Neuroblastoma
98
C. Tyrosine
99
B. T3 is about 10-fold more active than T4
100
B. Total T3 and T4 are influenced by the level of thyroxine-binding globulin